Conference Proceedings
Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study
Gerard Socie, Hubert Schrezenmeier, Petra Muus, Jeffrey Szer, Alvaro Urbano-Ispizua, Jaroslaw P Maciejewski, Robert A Brodsky, Monica Bessler, Yuzuru Kanakura, Wendell F Rosse, Gus Khursigara, Camille L Bedrosian, Peter Hillmen
BLOOD | AMER SOC HEMATOLOGY | Published : 2012
Abstract
Abstract Abstract 3480 Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic and life-threatening hematopoietic stem cell disorder characterized by uncontrolled complement-mediated hemolysis. PNH, in large part due to chronic hemolysis and platelet hyperactivation, is associated with thromboembolism (TE), one of the leading causes of disease mortality. Eculizumab, a monoclonal antibody that inhibits terminal complement activation, has been shown in clinical trials to reduce hemolysis and the incidence of TE. The International PNH Registry provides the opportunity to understand from real world experience the impac..
View full abstract